Etravirine concentrations in CSF in HIV-infected patients

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 6, 2012, Pages 1446-1448

  Tiraboschi, J M ^a   Niubo, J ^a   Vila, A ^a   Perez Pujol, S ^a   Podzamczer, D ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Antiretroviral; CNS; Neurocognitive impairment

Indexed keywords

ETRAVIRINE;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; LIQUID CHROMATOGRAPHY; MALE; REAL TIME POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; TREATMENT DURATION; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; BLOOD; CEREBROSPINAL FLUID; CHROMATOGRAPHY, LIQUID; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; MALE; MIDDLE AGED; PLASMA; PYRIDAZINES; REAL-TIME POLYMERASE CHAIN REACTION; TANDEM MASS SPECTROMETRY; VIRAL LOAD;

EID: 84861110096     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks048     Document Type: Article

References (10)

1. Letendre S, Ellis R, Everall I et al. Neurologic complications of HIV disease and their treatment. Top HIV Med 2009; 17: 46-56.
2. Letendre S, Marquie-Beck J, Capparelli E et al. Validation of the CNS penetration-effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65: 65-70.
3. Antinori A, Perno CF, Giancola ML et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005; 15: 1787-93.
4. Zhou XJ, Havlir DV, Richman DD et al. Plasma population pharmacokinetics and penetration into cerebrospinal fluid of indinavir in combination with zidovudine and lamivudine in HIV-1-infected patients. AIDS 2000; 14: 2869-76.
5. 50 for wild-type HIV. J Antimicrob Chemother 2011; 66: 354-7.
6. Yilmaz A, Gisslén M, Spudich S et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 2009; 4: e6877.
7. Tiraboschi JM, Niubo J, Curto J et al. Maraviroc concentrations in cerebrospinal fluid in HIV-infected patients. J Acquir Immune Defic Syndr 2010; 55: 606-9.
8. Couzigou C, Seang S, Morand-Joubert L. Efficacy of etravirine for treatment of acute HIV meningoencephalitis. Clin Infect Dis 2009; 48: e62-5.
9. European Medicines Agency. Summary of Product Characteristics. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000900/WC500034180.pdf (31 January 2012, date last accessed).
10. Best B, Letendre S, Croteau D et al. Therapeutic darunavir and etravirine concentrations in cerebrospinal fluid. In: Abstracts of the Eighteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2011. Abstract 643. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.